PSMA PET scanning in practice
Prostate cancer is the second most common cancer in the world, predicted to rise by 15% by 2025, while detection in late stage disease increased from 3.9% to 8.2% over the past decade in the USA.
Primary investigations for clinical diagnosis and staging of prostate cancer include blood tests, biopsy and imaging techniques such as CT, MRI and bone scans. The advent of multiparametric MRI has significantly addressed the shortcomings of biopsy (low sensitivity for disease-avid pathology), while providing better classification of high risk cancers, and triaging of patients for active monitoring.
The content on this page is provided by the individuals concerned and does not represent the views or opinions of RAD Magazine.
